Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3).

COVID-19 HIV Organ transplant SARS-CoV-2 SARS-CoV-2 vaccine Vaccine bivalent vaccine

Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
07 Jun 2024
Historique:
received: 01 02 2024
revised: 23 05 2024
accepted: 29 05 2024
medline: 7 6 2024
pubmed: 7 6 2024
entrez: 7 6 2024
Statut: aheadofprint

Résumé

Bivalent mRNA vaccines, designed to combat emerging SARS-CoV-2 variants, incorporate ancestral strains and a new variant. Our study assessed the immune response in previously vaccinated individuals of the Swiss HIV Cohort Study (SHCS) and the Swiss Transplant Cohort Study (STCS) following bivalent mRNA vaccination. Eligible SHCS and STCS participants received approved bivalent mRNA SARS-CoV-2 vaccines (mRNA-1273.214 or BA.1-adapted BNT162b2) within clinical routine. Blood samples were collected at baseline, 4 weeks, 8 weeks, and 6 months post vaccination. We analyzed the proportion of participants with anti-spike protein antibody response ≥1642 units/ml (indicating protection against SARS-CoV-2 infection), and in a subsample T-cell response (including mean concentrations), stratifying results by cohorts and population characteristics. In SHCS participants, baseline anti-spike antibody concentrations ≥1642 were observed in 87% (96/112), reaching nearly 100% at follow-ups. Among STCS participants, 58% (35/60) had baseline antibodies ≥1642, increasing to 80% at 6 months. Except for lung transplant recipients, all participants showed a five-fold increase in geometric mean antibody concentrations at 4 weeks and a reduction by half at 6 months. At baseline, T-cell responses were positive in 96% (26/27) of SHCS participants and 36% (16/45) of STCS participants (moderate increase to 53% at 6 months). Few participants reported SARS-CoV-2 infections, side-effects, or serious adverse events. Bivalent mRNA vaccination elicited a robust humoral response in individuals with HIV or solid organ transplants, with delayed responses in lung transplant recipients. Despite a waning effect, antibody levels remained high at 6 months and adverse events were rare.

Sections du résumé

BACKGROUND BACKGROUND
Bivalent mRNA vaccines, designed to combat emerging SARS-CoV-2 variants, incorporate ancestral strains and a new variant. Our study assessed the immune response in previously vaccinated individuals of the Swiss HIV Cohort Study (SHCS) and the Swiss Transplant Cohort Study (STCS) following bivalent mRNA vaccination.
METHODS METHODS
Eligible SHCS and STCS participants received approved bivalent mRNA SARS-CoV-2 vaccines (mRNA-1273.214 or BA.1-adapted BNT162b2) within clinical routine. Blood samples were collected at baseline, 4 weeks, 8 weeks, and 6 months post vaccination. We analyzed the proportion of participants with anti-spike protein antibody response ≥1642 units/ml (indicating protection against SARS-CoV-2 infection), and in a subsample T-cell response (including mean concentrations), stratifying results by cohorts and population characteristics.
RESULTS RESULTS
In SHCS participants, baseline anti-spike antibody concentrations ≥1642 were observed in 87% (96/112), reaching nearly 100% at follow-ups. Among STCS participants, 58% (35/60) had baseline antibodies ≥1642, increasing to 80% at 6 months. Except for lung transplant recipients, all participants showed a five-fold increase in geometric mean antibody concentrations at 4 weeks and a reduction by half at 6 months. At baseline, T-cell responses were positive in 96% (26/27) of SHCS participants and 36% (16/45) of STCS participants (moderate increase to 53% at 6 months). Few participants reported SARS-CoV-2 infections, side-effects, or serious adverse events.
CONCLUSIONS CONCLUSIONS
Bivalent mRNA vaccination elicited a robust humoral response in individuals with HIV or solid organ transplants, with delayed responses in lung transplant recipients. Despite a waning effect, antibody levels remained high at 6 months and adverse events were rare.

Identifiants

pubmed: 38848312
pii: 7689653
doi: 10.1093/infdis/jiae291
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Abela I (A)
Aebi-Popp K (AP)
Anagnostopoulos A (A)
Battegay M (B)
Bernasconi E (B)
Braun D L (B)
Bucher H C (B)
Calmy A (C)
Cavassini M (C)
Ciuffi A (C)
Dollenmaier G (D)
Egger M (E)
Elzi L (E)
Fehr J (F)
Fellay J (F)
Furrer H (F)
Fux C A (F)
Günthard H F (G)
Hachfeld A (H)
Haerry D (H)
Hasse B (H)
Hirsch H H (H)
Hoffmann M (H)
Hösli I (H)
Huber M (H)
Jackson-Perry D (JP)
Kahlert C R (K)
Kaiser L (K)
Keiser O (K)
Klimkait T (K)
Kouyos R D (K)
Kovari H (K)
Kusejko K (K)
Labhardt N (L)
Leuzinger K (L)
Martinez de Tejada B (MT)
Marzolini C (M)
Metzner K J (M)
Müller N (M)
Nemeth J (N)
Nicca D (N)
Notter J (N)
Paioni P (P)
Pantaleo G (P)
Perreau M (P)
Rauch A (R)
Salazar-Vizcaya L (SV)
Schmid P (S)
Speck R (S)
Stöckle M (S)
Tarr P (T)
Trkola A (T)
Wandeler G (W)
Weisser M (W)
Yerly S (Y)
Patrizia Amico (P)
John-David Aubert (JD)
Vanessa Banz (V)
Sonja Beckmann (S)
Guido Beldi (G)
Christoph Berger (C)
Ekaterine Berishvili (E)
Annalisa Berzigotti (A)
Isabelle Binet (I)
Pierre-Yves Bochud (PY)
Sanda Branca (S)
Heiner C Bucher (HC)
Emmanuelle Catana (E)
Anne Cairoli (A)
Yves Chalandon (Y)
Sabina De Geest (S)
Olivier De Rougemont (O)
Sophie De Seigneux (S)
Michael Dickenmann (M)
Joëlle Lynn Dreifuss (J)
Michel Duchosal (M)
Thomas Fehr (T)
Sylvie Ferrari-Lacraz (S)
Christian Garzoni (C)
Déla Golshayan (D)
Nicolas Goossens (N)
Fadi Haidar (F)
Jörg Halter (J)
Dominik Heim (D)
Christoph Hess (C)
Sven Hillinger (S)
Hans H Hirsch (HH)
Patricia Hirt (P)
Linard Hoessly (L)
Günther Hofbauer (G)
Uyen Huynh-Do (U)
Franz Immer (F)
Michael Koller (M)
Bettina Laesser (B)
Frédéric Lamoth (F)
Roger Lehmann (R)
Alexander Leichtle (A)
Oriol Manuel (O)
Hans-Peter Marti (HP)
Michele Martinelli (M)
Valérie McLin (V)
Katell Mellac (K)
Aurélia Merçay (A)
Karin Mettler (K)
Nicolas J Mueller (NJ)
Ulrike Müller-Arndt (U)
Beat Müllhaupt (B)
Mirjam Nägeli (M)
Graziano Oldani (G)
Manuel Pascual (M)
Jakob Passweg (J)
Rosemarie Pazeller (R)
Klara Posfay-Barbe (K)
Juliane Rick (J)
Anne Rosselet (A)
Simona Rossi (S)
Silvia Rothlin (S)
Frank Ruschitzka (F)
Thomas Schachtner (T)
Stefan Schaub (S)
Alexandra Scherrer (A)
Aurelia Schnyder (A)
Macé Schuurmans (M)
Simon Schwab (S)
Thierry Sengstag (T)
Federico Simonetta (F)
Susanne Stampf (S)
Jürg Steiger (J)
Guido Stirnimann (G)
Ueli Stürzinger (U)
Christian Van Delden (C)
Jean-Pierre Venetz (JP)
Jean Villard (J)
Julien Vionnet (J)
Madeleine Wick (M)
Markus Wilhelm (M)
Patrick Yerly (P)

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Auteurs

Alain Amstutz (A)

Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Oslo Center for Biostatistics and Epidemiology (OCBE), Oslo University Hospital, University of Oslo, Oslo, Norway.
Bristol Medical School, University of Bristol, Bristol, UK.

Frédérique Chammartin (F)

Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.

Annette Audigé (A)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

Anna L Eichenberger (AL)

Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Dominique L Braun (DL)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

Patrizia Amico (P)

Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Switzerland.

Marcel P Stoeckle (MP)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Switzerland.

Barbara Hasse (B)

Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

Matthaios Papadimitriou-Olivgeris (M)

Infectious Diseases Service and Transplantation Center, Lausanne University Hospital, Lausanne, Switzerland.

Oriol Manuel (O)

Infectious Diseases Service and Transplantation Center, Lausanne University Hospital, Lausanne, Switzerland.

Cédric Bongard (C)

Division of Pulmonology, Departement of Medicine, University Hospital of Lausanne, Lausanne, Switzerland.

Macé M Schuurmans (MM)

Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland.

René Hage (R)

Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland.

Dominik Damm (D)

Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland.

Michael Tamm (M)

Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland.

Nicolas J Mueller (NJ)

Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

Andri Rauch (A)

Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Huldrych F Günthard (HF)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

Michael T Koller (MT)

Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Switzerland.
Swiss Transplant Cohort Study, University Hospital Basel, Basel, Switzerland.

Christof M Schönenberger (CM)

Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.

Alexandra Griessbach (A)

Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.

Niklaus D Labhardt (ND)

Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.

Roger D Kouyos (RD)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

Alexandra Trkola (A)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

Katharina Kusejko (K)

Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

Heiner C Bucher (HC)

Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.

Irene A Abela (IA)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

Matthias Briel (M)

Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.

Benjamin Speich (B)

Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.

Classifications MeSH